Y0000469
二丙酸倍氯米松
European Pharmacopoeia (EP) Reference Standard
别名:
9-氯-11β,17,21-三羟基-16β-甲基孕甾-1,4-二烯-3,20-二酮-17,21-二丙酸酯
等级
pharmaceutical primary standard
API类
beclometasone
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C
InChI
1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
InChI key
KUVIULQEHSCUHY-XYWKZLDCSA-N
基因信息
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Beclometasone dipropionate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Repr. 2 - STOT RE 2
靶器官
Adrenal gland,Immune system,Bone
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
涉药品监管产品
此项目有
P Small et al.
Annals of allergy, 49(3), 127-130 (1982-09-01)
Beclomethasone dipropionate has been demonstrated to be effective in the treatment of seasonal and perennial rhinitis. Comparative studies with other medications are lacking. Adverse reactions are frequent but minor. No alterations of the hypothalamic-pituitary-adrenal axis, nasal mucosal histology or bacterial
J P Seale et al.
Respiratory medicine, 92 Suppl A, 9-15 (1998-12-16)
Reformulation of beclomethasone dipropionate (BDP) in the chlorofluorocarbon (CFC)-free propellant hydrofluoroalkane-134a (HFA) gave the opportunity to produce a solution formulation that provides a greater total mass of fine drug particles than the current CFC suspension metered dose inhaler (MDI). The
B Davies
The British journal of clinical practice, 47(2), 87-93 (1993-03-01)
Several reports have claimed that beclomethasone dipropionate (BDP) and budesonide (BUD) differ with regard to therapeutic efficacy and associated adverse effects, based either upon clinical data, or upon theoretical considerations. Although long-term comparisons are lacking, the consensus of numerous studies
A R Boobis
Respiratory medicine, 92 Suppl B, 2-6 (1999-04-08)
The physicochemical and pharmacokinetic characteristics of BDP and budesonide are somewhat different, but the overall result is that both are well suited for use as inhaled corticosteroids. Both BDP and budesonide are metabolized primarily by the liver, with one of
P Chervinsky
Clinical therapeutics, 18(5), 790-796 (1996-09-01)
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持